ACNS1721: A Phase 2 Study of Veliparib (ABT-888 IND # 139199) and Local Irradiation Followed by Maintenance Veliparib and Temozolomide in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Newly Diagnosed High-grade Glioma (hgg) Without H3 K27m Or Brafv600e Mutations
  • Age: Between 3 - 25 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Stratum 1 (IDH wild-type): Patients must be = 3 years of age and = 21 years of age at the time of enrollment. Stratum 2 (IDH mutant): Patients must be = 3 years of age and = 25 years of age at the time of enrollment. 2) Patients must have eligibility confirmed by rapid central pathology and central molecular screening reviews performed on APEC14B1 (see Section 3.1): • Newly-diagnosed high-grade glioma such as anaplastic astrocytoma or glioblastoma. • Negative results for H3 K27M by immunohistochemistry (IHC). • Negative results for BRAFV600E mutation by Next-Generation Sequencing (NGS).

You may not be eligible for this study if the following are true:

  • 1) Patients with the following histologies: - Diffuse astrocytoma (Grade 2) - Oligodendrogliomas (any grade) - Pleomorphic xanthoastrocytoma (PXA, any grade) 2) Patients with primary tumor location of brainstem or spinal cord. 3) Patients with M+ disease (defined as neuraxis dissemination either by imaging or by cytology).


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.